IMMUNITYBIO, INC. (IBRX) Quick Ratio
- Quick ratio · latest quarter: Value 5.35×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 5.35× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $410.84M ÷ $76.73M ≈ 5.35× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 410.84M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 76.73M USD | Liabilities, Current |
| Cash and equivalents | 75.67M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 281.70M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 53.47M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 1.94M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $410.84M | $76.73M | $75.67M | $281.70M | $53.47M | $1.94M | 5.35× |
| 2026-03-31 | $424.15M | $67.95M | $205.19M | $175.69M | $43.27M | $547.00K | 6.24× |
| 2025-12-31 | $285.39M | $61.75M | $88.33M | $154.48M | $42.57M | $910.00K | 4.62× |
| 2025-09-30 | $289.83M | $57.13M | $60.24M | $197.57M | $32.02M | $6.70M | 5.07× |
| 2025-06-30 | $175.78M | $50.64M | $137.66M | $16.00M | $22.13M | $6.64M | 3.47× |
| 2025-03-31 | $78.62M | $49.20M | $60.66M | $931.00K | $17.03M | $8.44M | 1.60× |
| 2024-12-31 | $152.17M | $54.94M | $143.43M | $6.38M | $2.36M | $8.27M | 2.77× |
| 2024-09-30 | $134.54M | $60.96M | $111.97M | $18.40M | $4.17M | $1.96M | 2.21× |
| 2024-06-30 | $219.01M | $62.11M | $130.10M | $87.88M | $1.03M | $1.81M | 3.53× |
| 2024-03-31 | (m) | $53.76M | $133.03M | $37.46M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $58.28M | $265.45M | $1.01M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $90.32M | $177.96M | $11.83M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $613.48M | $43.51M | $2.45M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $564.95M | $88.48M | $2.79M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $500.86M | $104.64M | $2.54M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $70.84M | $104.16M | $6.90M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $376.05M | $61.90M | $21.04M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $381.01M | $36.38M | $155.95M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $369.00M | $181.10M | $136.01M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $65.41M | $64.52M | $15.85M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $74.43M | $83.96M | $19.97M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $79.86M | $44.68M | $38.59M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $24.65M | $11.44M | $54.77M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $20.66M | $27.69M | $61.35M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $17.05M | $102.70M | $7.92M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $14.25M | $16.95M | $23.26M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $11.56M | $15.51M | $36.14M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $12.52M | $18.29M | $47.77M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $12.43M | $17.28M | $66.77M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $27.70M | $22.28M | $76.27M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $27.26M | $16.82M | $57.33M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $30.40M | $15.31M | $68.00M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $20.19M | $16.12M | $88.82M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $19.40M | $11.20M | $110.59M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $20.87M | $23.87M | $104.28M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $28.67M | $20.92M | $131.35M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $36.88M | $39.04M | $136.47M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $14.20M | $13.60M | $177.37M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $12.55M | $8.08M | $190.84M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $10.23M | $31.40M | $177.85M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $10.04M | $38.22M | $175.54M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $7.86M | $63.25M | $158.51M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $6.15M | $175.91M | $118.31M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $6.68M | $358.62M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $120.44M | (m) | $45.00K | (m) | (m) |
| 2015-03-31 | (m) | (m) | $49.85M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $59.10M | (m) | $145.00K | (m) | (m) |
| 2014-09-30 | (m) | (m) | $3.18M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $3.99M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $351.00K | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $116.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |